OakChart

AVITA Medical Inc

RCELHealthcare·Medical Devices·USA·Small·NASD·Nov 11 • 1:04 PM ET

17.29-0.36 (-2.04%)
2026-11-11 19:05 CET
Market cap
438.48 USD m
Revenue, TTM
84.68 USD m
Net income, TTM
-36.12 USD m
Free cash flow, TTM
-19.34 USD m
EPS diluted, TTM
-1.18
P/E
-
Compare

Price

RCEL against its 20, 50 and 200-day averages
2050200beatmiss
5.0010.0015.003.6M7.3MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26RCELclose 17.2920-day 15.5650-day 13.20200-day 7.0517.2952w high52w low

6.2% under the 52-week high of 18.43 on 9 Nov 2026. 52-week low 3.22 on 7 Jan 2026. Last 15 sessions, 29.1% high to low

Profile

RCEL
52-week range, 93% of the way up
3.2218.43

AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.

Employees226
IPOMar 29, 2012
Beta2.00
ATR, 14d1.14
Rel volume1.32
Short float11.52%
Insider own1.93%
Inst own21.25%

Snapshot

6 groups

Valuation

Index-
Market Cap429.48M
Enterprise Value466.11M
Income-36.12M
Sales84.68M
Book/sh-1.00
Cash/sh0.42
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees226
IPOMar 29, 2012

Ratios

P/E-
Forward P/E-
PEG-
P/S5.07
P/B-
P/C40.90
P/FCF-
EV/EBITDA-
EV/Sales5.50
Quick Ratio0.99
Current Ratio1.20
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.18
EPS next Y-0.38
EPS next Q-0.15
EPS this Y47.71%
EPS next Y57.80%
EPS next 5Y63.37%
EPS past 3/5Y-17.81% 3.38%
Sales past 3/5Y27.66% 38.09%
EPS Y/Y TTM34.83%
Sales Y/Y TTM16.96%
EPS Q/Q56.59%
Sales Q/Q53.05%
EarningsNov 05 AMC
EPS/Sales Surpr.16.46% 16.84%

Ownership

Insider Own1.93%
Insider Trans11.44%
Inst Own21.25%
Inst Trans-2.52%
ROA-65.36%
ROE-1746.27%
ROIC-224.37%
Gross Margin82.36%
Oper. Margin-33.89%
Profit Margin-42.65%
SMA2011.15%
SMA5031.01%
SMA200145.40%
Trades-

Technical

Shs Outstand30.96M
Shs Float24.36M
Short Float11.52%
Short Ratio6.63
Short Interest2.81M
52W High18.43 -6.19%
52W Low3.22 436.96%
Volatility9.31% 7.10%
ATR (14)1.14
RSI (14)67.91
Beta2.00
Rel Volume1.32
Avg Volume423.57K
Volume319,066

Performance

Perf Week5.94%
Perf Month29.42%
Perf Quarter115.86%
Perf Half Y305.87%
Perf YTD401.16%
Perf Year336.62%
Perf 3Y53.14%
Perf 5Y4.41%
Perf 10Y70.34%
Recom1.33
Target Price17.72
Prev Close17.65
Price17.29
Change %-2.04%

Analyst ratings

latest 10 of 12
DateActionAnalystRating changeTargetImplied
Aug 07, 2026UpgradeBBTIG ResearchNeutral → Buy$7-59.5%
May 15, 2026UpgradeLLake StreetHold → Buy$6-65.3%
Mar 05, 2026InitiatedNNorthland CapitalOutperform$10-42.2%
Nov 20, 2025UpgradeBBTIG ResearchSell → Neutral
Aug 08, 2025DowngradeBBTIG ResearchNeutral → Sell$3-82.6%
Dec 24, 2024InitiatedDD. Boral CapitalBuy$25+44.6%
Apr 11, 2024DowngradeBBTIG ResearchBuy → Neutral
Jun 27, 2023InitiatedCCantor FitzgeraldOverweight$23+33.0%
Mar 02, 2021InitiatedPPiper SandlerOverweight$27+56.2%
Aug 27, 2020InitiatedBBofA SecuritiesBuy$42+142.9%

Peers

Mkt cap
TickerCompanyMkt cap
MDXGMimedx Group Inc496.16M
ORGOOrganogenesis Holdings Inc131.10M
SNWVSanuwave Health Inc13.74M
SMTISanara MedTech Inc291.53M
TELATELA Bio Inc37.78M
AXGNAxogen Inc3.21B
BVSBioventus Inc940.09M
ELUTElutia Inc41.98M
ESTAEstablishment Labs Holdings Inc2.12B
CUPRCuprina Holdings (Cayman) Ltd10.37M

Insider trading

8 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Woody Joseph FralinDirectorJun 09 '26Buy4.005,20020,800107,961Jun 10 09:17 PM
Woody Joseph FralinDirectorJun 09 '26Buy4.1910,00041,900102,761Jun 09 04:58 PM
Woody Joseph FralinDirectorJun 03 '26Buy4.0910,00040,94992,761Jun 05 05:00 PM
Woody Joseph FralinDirectorJun 01 '26Buy4.3010,00043,00010,000Jun 03 04:30 PM
Woody Joseph FralinDirectorJun 02 '26Buy4.1910,00041,93620,000Jun 03 04:30 PM
O'Toole David DCFOMay 20 '26Buy4.262,0008,520145,927May 20 04:30 PM
O'Toole David DCFOMay 19 '26Buy4.242,0008,480143,927May 19 04:30 PM
O'Toole David DCFOFeb 19 '26Buy4.153,00012,450140,127Feb 23 04:30 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 206
  • AVITA Medical to Host Investor Webinar Briefing (GlobeNewswire)
  • AVITA Medical's 53% Growth And Second Guidance Raise Remove Going-Concern Doubt, But A Flat Q4 Guide Tests A Stock Up 171% (Earnings Whispers) +5.80%
  • AVITA Medical Reports Third Quarter Results (GlobeNewswire)
  • AVITA Medical Announces National Medicare Physician Payment Framework and Simplified Billing Codes for RECELL Procedures in 2027 (GlobeNewswire)
  • AVITA Medical's Q3 Must Justify A 168% Rally As Cash Breakeven Approaches (Earnings Whispers)
  • Loading…
  • AVITA Medical to Announce Third Quarter 2026 Financial Results (GlobeNewswire) +5.02% +10.80%
  • AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference (GlobeNewswire) +6.85%
  • AVITA Medical Announces Positive PermeaDerm Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes (GlobeNewswire) +24.68%
  • AVITA Medical to Host Investor Webinar Briefing (GlobeNewswire)
  • AVITA Medical Announces Participation at Canaccord Genuity Growth Conference (GlobeNewswire) +63.58%
  • Avita Medical Shares Surge After Record Second-Quarter Performance (InvestorsHub)
  • AVITA Medical Inc (AVHHL) (Q2 2026) Earnings Call Highlights: Revenue Surges 18% to $21. ... (GuruFocus.com)
  • AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven (GlobeNewswire) +6.26%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.200-0.239-0.20026.1122.355
2026Q22026-08-06-0.250-0.293-0.24921.4920.255
2026Q12026-05-14-0.350-0.292-0.34719.2518.305
2025Q42026-02-12-0.380-0.364-0.38317.4317.845
2025Q32025-11-06-0.460-0.332-0.46417.0618.377
2025Q22025-08-07-0.380-0.250-0.37618.4222.517
2025Q12025-05-08-0.530-0.307-0.52818.5120.757
2024Q42025-02-13-0.440-0.429-0.44318.2120.728
2024Q32024-11-07-0.620-0.434-0.62419.5519.447
2024Q22024-08-08-0.600-0.482-0.59815.1814.527
2024Q12024-05-13-0.730-0.345-0.72811.1011.086
2023Q42024-02-22-0.280-0.379-0.27714.2014.206
2023Q32023-11-09-0.340-0.435-0.34313.6513.406
2023Q22023-08-10-0.410-0.313-0.41111.7511.306
2023Q12023-05-11-0.370-0.270-0.36610.5510.286
2022Q32022-05-17---0.3807.54--

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.375-0.248-0.09911.4811.74
2020FY-2.070-0.706-2.07114.2616.58
2021FY-1.170-2.010-1.17021.5025.34
2022FY-1.070-1.116-1.06734.4234.18
2023FY-1.400-1.691-1.39750.1450.14
2024FY-2.390-2.257-2.38963.8966.51
2025FY-1.740-1.799-1.74070.8871.49
2026FY--0.910--91.79
2027FY--0.384--114.4
2028FY--0.086--137.8
2029FY-2.760--411.37
2030FY-3.620--497.55

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0644025.9824.9026.80
2026Q4S2026-10-2140024.0023.3024.60
2026Q4S2026-08-1844024.0023.3024.60
2026Q4S2026-08-0744024.0023.3024.60
2026Q4S2026-07-2940022.5321.6023.10
2026Q4S2026-06-2941222.5321.6023.10
2026Q4S2026-06-2541222.5521.6023.20
2026Q4S2026-05-2651222.7821.6023.69
2026Q4S2026-05-1561222.8221.6023.69
2026Q4S2026-03-3160022.9822.3023.69
2026Q4S2026-03-3061022.9822.3023.69
2026Q4S2026-03-0461122.9822.3023.69
2026Q4S2026-02-2851122.8422.3023.30
2026Q4S2026-02-1551222.8422.3023.30

Estimate history

EPS, annual-0.065-0.058-0.069-0.099-2.071-1.067-1.397-2.389-1.744-1.1807
Period201620172018201920202022202320242025TTM
EPS, quarterly-0.624-0.443-0.528-0.376-0.464-0.383-0.347-0.249-0.202
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0.7290.890.9295.51214.26334.42150.14364.25171.6184.68
Period201620172018201920202022202320242025TTM
Sales, quarterly19.54618.40618.51418.41817.06217.61519.25121.70226.114
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual119.445141.902255.476374.2621.46825.20825.68226.35430.57230.963
Period201620172018201920202022202320242025MRQ
Shares, quarterly26.21826.35426.43526.61430.49330.57230.77730.92730.963
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2020FY2019FY2018FY
Total Revenue84.6871.6164.2550.1434.42-14.265.510.93
Cost of Goods Sold Incl. D&A14.9412.799.097.786.04-2.971.210.40
Gross Profit69.7558.8255.1642.3628.38-11.294.300.53
Selling, General and Administrative Excl. Other98.44100.75111.66165.4259.19-57.9035.7822.27
Research and Development21.1020.8420.3620.8213.86-8.4610.279.77
Other Operating Expense0.000.000.000.000.00-0.000.000.00
Operating Income-28.70-41.93-56.51-123.06-30.81--46.60-31.49-21.73
Interest Expense5.945.005.361.140.02-0.030.030.02
Unusual Expense-4.07-2.200.00-79.000.00-0.00--
Net Income Before Taxes-36.05-48.58-61.79-35.32-26.63--42.03-25.28-13.87
Income Taxes0.070.010.050.070.04-0.00-0.13-1.07
Consolidated Net Income-36.12-48.59-61.85-35.38-26.67--42.03-25.15-12.80
Net Income From Continuing Operations-36.12-48.59-61.85-35.38-26.67--42.03-25.15-12.80
Net Income-36.12-48.59-61.85-35.38-26.67--42.03-25.15-12.80
EPS (Recurring)-1.26-1.80-2.39-3.58-1.07--2.07-0.10-0.07
EPS (Basic, Before Extraordinaries)-1.18-1.74-2.39-1.40-1.07--2.07-0.10-0.07
EPS (Diluted)-1.18-1.74-2.39-1.40-1.07--2.07-0.10-0.07
EBITDA-26.17-39.59-55.41-121.34-29.21--45.64-31.22-21.62
Non-Operating Income (Expense)-5.49-3.840.089.894.20-4.616.237.88
Other After Tax Adjustments0.000.000.000.000.00-0.000.000.00
Stock Option Compensation Expense9.817.5210.666.625.16-12.031.351.00
Price To Sales Ratio4.281.345.166.934.79-43.451,354.721,025.99
Gross Margin82.3682.1385.8584.4882.45-79.1677.9757.32
Operating Margin-33.89-58.56-87.95-245.42-89.51--326.75-571.26-2,339.81
Net Margin-42.65-67.85-96.26-70.56-77.47--294.68-456.31-1,377.90
Shares Outstanding30.9630.5726.3525.6825.21-21.47374.26255.48
Market Capitalization438.48438.48317.99340.84163.96-655.6310,228.511,125.00

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue26.1121.7019.2517.6117.0618.4218.5118.41
Cost of Goods Sold Incl. D&A4.173.943.523.303.193.472.832.28
Gross Profit21.9417.7715.7314.3113.8814.9515.6816.13
Selling, General and Administrative Excl. Other24.5724.6224.5324.7223.0326.1027.5126.08
Research and Development4.705.085.635.693.755.126.284.85
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.63-6.86-8.80-10.41-9.15-11.15-11.83-9.96
Interest Expense1.481.461.741.251.271.251.231.30
Unusual Expense-2.10-0.200.43-2.200.000.000.000.00
Net Income Before Taxes-6.16-7.63-10.62-11.64-13.17-9.92-13.85-11.57
Income Taxes0.070.03-0.01-0.020.020.000.010.02
Consolidated Net Income-6.22-7.66-10.61-11.62-13.19-9.92-13.86-11.59
Net Income From Continuing Operations-6.22-7.66-10.61-11.62-13.19-9.92-13.86-11.59
Net Income-6.22-7.66-10.61-11.62-13.19-9.92-13.86-11.59
EPS (Recurring)-0.25-0.25-0.34-0.43-0.46-0.38-0.53-0.44
EPS (Basic, Before Extraordinaries)-0.20-0.25-0.35-0.38-0.46-0.38-0.53-0.44
EPS (Diluted)-0.20-0.25-0.35-0.38-0.46-0.38-0.53-0.44
EBITDA-2.04-6.25-8.18-9.71-8.58-10.60-11.31-9.58
Non-Operating Income (Expense)-4.150.490.35-2.18-2.752.48-0.79-0.32
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.321.570.876.060.482.112.132.21
Price To Sales Ratio4.281.681.561.462.001.862.985.21
Gross Margin84.0281.8781.7081.2481.3281.1784.7087.61
Operating Margin-10.07-31.59-45.73-59.09-53.65-60.53-63.88-54.10
Net Margin-23.83-35.31-55.12-65.97-77.29-53.86-74.86-62.96
Shares Outstanding30.9630.9330.7830.5730.4926.6126.4326.35
Market Capitalization438.48102.6091.9285.71126.95131.42202.22317.99

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments18.1935.8989.0679.34-73.8420.3410.952.91
Short Term Receivables9.1111.967.944.71-2.512.094.021.59
Inventories6.937.275.602.13-1.130.740.850.80
Other Current Assets1.271.881.411.28-0.921.090.630.29
Total Current Assets35.4957.00104.0187.46-78.3924.2716.465.58
Net Property, Plant & Equipment11.5313.594.322.05-3.711.290.550.30
Total Investments and Advances0.000.000.006.93-0.000.000.000.00
Intangible Assets5.655.570.490.47-0.360.230.000.00
Other Assets3.733.552.831.36-0.000.000.000.00
Total Assets56.3979.71111.6498.26-82.4625.7817.015.88
Short Term Debt Incl. Current Port. of LT Debt43.910.900.900.61-0.540.000.000.00
Accounts Payable8.966.293.793.00-4.330.480.200.76
Other Current Liabilities9.8112.968.517.08-2.833.932.671.19
Total Current Liabilities62.6820.1613.2010.69-7.714.412.871.95
Long Term Debt2.1445.0941.510.31-1.920.040.100.00
Provision for Risks Charges0.003.433.160.00-0.000.000.000.00
Other Liabilities4.533.320.360.70-0.430.430.000.00
Total Liabilities69.3572.0058.2311.70-10.064.882.971.95
Non-Equity Reserves3.703.214.361.83-0.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.00-0.000.000.000.00
Common Equity-16.654.5049.0684.74-72.4020.9014.043.93
Total Shareholders Equity-16.654.5049.0684.74-72.4020.9014.043.93
Accumulated Minority Interest0.000.000.000.00-0.000.000.000.00
Total Equity-16.654.5049.0684.74-72.4020.9014.043.93
Total Liabilities & Stockholders Equity56.3979.71111.6498.26-82.4625.7817.015.88
Book Value Per Share-0.540.171.913.36-3.370.060.050.03
Tangible Book Value Per Share-0.73-0.041.893.34-3.360.060.050.03
Full-Time Employees226260207126-98875537
Price to Book Ratio-17.6127.455.571.88-9.06464.9999.04221.38
Return on Assets-71.40-64.64-33.71-23.83--77.66-117.56-111.84-141.29
Return on Equity--230.96-52.89-26.61--90.09-143.95-142.47-192.24
Return on Invested Capital--124.73-39.06-31.35--56.55-120.09-90.53-220.95
Quick Ratio0.462.477.467.98-10.025.335.442.45
Current Ratio0.572.837.888.18-10.175.505.742.86

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2020FY2019FY2018FY
Net Income-36.31-48.59-61.85-35.38-26.67--42.03-25.15-12.80
Depreciation2.542.351.131.721.60-0.970.270.11
Other Funds (Non Cash)10.7111.6116.462.227.17-16.991.800.86
Funds from Operations-23.06-34.63-44.26-31.44-17.89--24.08-23.08-11.83
Extraordinary Item0.000.000.000.000.00-0.000.000.00
Changes in Working Capital3.273.44-4.68-6.57-1.20-1.333.42-0.85
Cash from Operating Activities-19.79-31.20-48.94-38.01-19.09--22.75-19.66-12.68
Capital Expenditures0.38-1.10-9.33-1.45-0.53--0.85-1.28-0.39
Net Assets From Acquisitions0.000.000.000.000.00-0.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.00-0.000.000.00
Purchase or Sale of Investments8.0914.1946.703.05-18.81-0.000.000.00
Purchase of Investments-5.92-13.31-24.50-78.76-74.36-0.000.000.00
Sale Or Maturity of Investments14.0127.5071.2081.8155.56-0.000.000.00
Other Uses-0.65-0.640.000.000.00-0.000.000.00
Other Sources0.000.000.000.000.00-0.000.000.00
Cash from Investing Activities7.8212.4537.361.61-19.33--0.85-1.28-0.39
Cash Dividends Paid0.000.000.000.000.00-0.000.000.00
Change in Capital Stock0.5914.142.140.960.90-77.0629.5421.64
Repurchase of Common Pref Stock0.000.000.000.000.00-0.000.000.00
Sale of Common Pref Stock0.5914.142.140.960.90-77.0629.5421.64
Proceedsfrom Stock Options0.4013.730.000.000.00-76.5829.2221.64
Issuance or Reduction of Debt, Net6.120.000.0038.760.00-0.000.000.00
Change in Long Term Debt6.120.000.0038.760.00-0.000.000.00
Issuance of Long Term Debt49.230.000.0038.760.00-0.000.000.00
Reduction of Long Term Debt-43.110.000.000.000.00-0.000.000.00
Net Financing Active Other Cash Flow0.250.801.370.660.00-0.000.000.00
Other Financing Activities Uses0.000.000.000.000.00-0.000.000.00
Cash from Financing Activities6.9514.943.5140.370.90-77.0629.5421.64
Exchange Rate Effect--0.00-0.02-0.03-0.001.53-0.02
Net Change in Cash-5.02-3.81-8.073.95-37.55-53.4710.138.55
Free Cash Flow-19.34-32.20-58.11-39.39-19.54--23.34-20.72-13.07
Preferred Dividends (Cash Flow)-0.000.000.000.00-0.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.00-0.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments10.5011.1414.2618.1923.3115.69
Short Term Receivables10.369.899.909.119.0511.37
Inventories4.805.296.126.937.247.54
Other Current Assets2.012.091.371.271.771.65
Total Current Assets27.6828.3931.6535.4941.3736.25
Net Property, Plant & Equipment9.7610.3310.8811.5313.0112.82
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets5.555.255.445.655.205.31
Other Assets3.813.803.583.734.143.75
Total Assets46.7947.7851.5456.3963.7358.13
Short Term Debt Incl. Current Port. of LT Debt0.0046.6646.1443.9142.4542.22
Accounts Payable4.846.427.228.968.117.27
Other Current Liabilities18.2015.6313.319.8111.2813.12
Total Current Liabilities23.0468.7166.6762.6861.8362.60
Long Term Debt47.131.821.982.142.322.37
Provision for Risks Charges0.000.000.000.001.861.90
Other Liabilities7.665.086.064.530.300.31
Total Liabilities77.8375.6274.7169.3566.3167.18
Non-Equity Reserves0.000.000.003.704.083.85
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-31.04-27.84-23.17-16.65-6.67-12.89
Total Shareholders Equity-31.04-27.84-23.17-16.65-6.67-12.89
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-31.04-27.84-23.17-16.65-6.67-12.89
Total Liabilities & Stockholders Equity46.7947.7851.5456.3963.7358.13
Book Value Per Share-1.00-0.90-0.75-0.54-0.22-0.48
Tangible Book Value Per Share-1.18-1.07-0.93-0.73-0.39-0.68
Full-Time Employees---226--
Price to Book Ratio-17.61-5.49-6.79-15.78-10.55-30.59
Return on Assets-65.36-81.36-74.88-71.40-67.07-70.67
Return on Equity-----1,746.27-935.73
Return on Invested Capital-38.65-----
Quick Ratio0.990.340.380.460.550.46
Current Ratio1.200.410.470.570.670.58

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-6.12-7.84-10.61-11.74-13.70-10.16
Depreciation0.590.620.630.710.600.56
Other Funds (Non Cash)4.712.412.141.456.610.97
Funds from Operations-0.82-4.82-7.84-9.58-6.49-8.63
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.201.19-2.234.110.96-1.80
Cash from Operating Activities-0.62-3.63-10.07-5.47-5.54-10.44
Capital Expenditures-0.11-0.11-0.020.62-0.98-0.53
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments1.964.062.060.00-4.287.73
Purchase of Investments0.03-0.04-3.94-1.97-8.08-3.50
Sale Or Maturity of Investments1.944.106.001.973.8011.22
Other Uses0.000.000.00-0.650.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities1.853.952.04-0.02-5.277.20
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.180.440.00-0.0314.050.01
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.180.440.00-0.0314.050.01
Proceedsfrom Stock Options-0.000.440.00-0.0314.020.00
Issuance or Reduction of Debt, Net-0.040.066.100.000.000.00
Change in Long Term Debt-0.040.066.100.000.000.00
Issuance of Long Term Debt-0.340.4849.080.000.000.00
Reduction of Long Term Debt0.29-0.42-42.980.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.250.010.55
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.140.506.100.2214.060.57
Net Change in Cash1.370.82-1.93-5.283.25-2.67
Free Cash Flow-0.73-3.74-10.09-4.78-6.50-10.97

Revenue breakdown

Consolidation, Policy2024: 228.00K 2025: 172.00K
Lease2024: 358.00K 2025: 731.00K
Other Wound Care Products2024: 1.05M 2025: 4.25M
RECELL2024: 62.61M 2025: 66.46M
Australia2024: 312.00K 2025: 200.00K
European Union2024: 155.00K 2025: 49.00K
Japan2024: 1.43M 2025: 2.09M
United Kingdom2024: 196.00K 2025: 486.00K
United States2024: 62.16M 2025: 68.79M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3011.52%2.8M24.4M484.41K
2026-10-1511.64%2.8M24.4M447.07K
2026-09-3011.87%2.9M24.3M442.53K
2026-09-1511.86%2.9M24.3M461.80K
2026-08-3112.08%2.9M24.3M452.95K
2026-08-1411.30%2.7M24.3M435.44K
2026-07-3110.91%2.6M23.9M295.72K
2026-07-1510.96%2.6M23.9M284.55K
2026-06-3010.59%2.5M23.9M271.75K
2026-06-1513.49%3.2M23.9M239.68K
2026-05-2913.77%3.3M24.0M229.94K
2026-05-1514.29%3.5M24.8M240.76K
2026-04-3013.91%3.4M24.6M225.60K
2026-04-1514.60%3.6M24.4M232.66K
2026-03-3115.67%3.8M24.4M228.38K
2026-03-1315.18%3.7M24.4M226.73K
2026-02-2715.64%3.8M24.4M226.74K
2026-02-1315.37%3.8M24.4M215.38K
2026-01-3015.33%3.8M24.6M209.68K
2026-01-1514.45%3.6M24.6M233.32K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.5013.9016.300.0011.3980.000.000.994-0.0170.000
call5.0011.4013.800.007.2460.000.000.953-0.1190.003
call7.509.2010.900.006.1800.000.000.924-0.1120.004
call10.006.708.402.954.4227.000.000.891-0.1060.005
call12.504.505.805.052.9092490.000.845-0.0950.006
call15.001.203.402.652.0212010.000.754-0.0800.009
call17.500.550.800.700.8083162.000.501-0.0540.011
call20.000.000.600.251.38412.000.000.286-0.0710.009
call22.500.000.750.001.8800.000.000.231-0.0870.008
put2.500.000.050.005.9630.000.00-0.006-0.0160.001
put5.000.000.750.357.40270.000.00-0.049-0.1140.003
put7.500.000.700.265.22581.000.00-0.075-0.1120.004
put10.000.000.750.403.72832.000.00-0.109-0.1050.005
put12.500.000.700.052.60734.000.00-0.155-0.0940.006
put15.000.000.750.191.6702080.00-0.243-0.0790.009
put17.500.601.151.050.9816.000.00-0.499-0.0520.011
put20.001.753.305.401.4731.000.00-0.709-0.0680.009
put22.503.005.800.001.8370.000.00-0.768-0.0840.008

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-028-KCurrent report2026-11-02SEC
2026-08-25S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-244/A2026-06-12SEC
2026-08-118-KCurrent report2026-08-05SEC
2026-08-068-K/A2026-06-03SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-088-KCurrent report2026-06-05SEC
2026-06-08424B5SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-048-KCurrent report2026-06-03SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-014Statement of changes in beneficial ownership of securities2026-05-29SEC
2026-06-014Statement of changes in beneficial ownership of securities2026-05-29SEC
2026-05-204Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-194Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-148-KCurrent report2026-05-14SEC
2026-05-018-KCurrent report2026-04-30SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-06188.59K500
2026-0517.00K200
2026-040000
2026-030000
2026-0212.45K100
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC5.37%
BlackRock, Inc.2.27%
MARSHALL WACE, LLP1.36%
GEODE CAPITAL MANAGEMENT, LLC1.36%
AQR CAPITAL MANAGEMENT LLC1.29%
Squarepoint Ops LLC1.02%
MORGAN STANLEY0.81%
VANGUARD FIDUCIARY TRUST CO0.73%
NewEdge Advisors, LLC0.60%
MACQUARIE GROUP LTD0.58%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.86%
VANGUARD EXTENDED MARKET INDEX FUND1.37%
Fidelity Extended Market Index Fund0.63%
Fidelity Small Cap Index Fund0.55%
iShares Micro-Cap ETF0.42%
VANGUARD RUSSELL 2000 INDEX FUND0.29%
Fidelity Total Market Index Fund0.24%
Goldman Sachs Absolute Return Tracker Fund0.24%
Fidelity Series Total Market Index Fund0.19%
iShares Core S&P Total U.S. Stock Market ETF0.18%

OakChart. RCEL. Cached 15 minutes.